Crossmark

CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms

Crossref DOI link: https://doi.org/10.1016/j.ejca.2024.114192

Published Print: 2024-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Haslam, Alyson

Ranganathan, Sruthi

Prasad, Vinay

Olivier, Timothée
Funding

Funding for this research was provided by:

Arnold Ventures LLC
License Information

Text and Data Mining valid from 2024-08-01

Text and Data Mining valid from 2024-08-01

Version of Record valid from 2024-06-28
More Information

This article is maintained by: Elsevier

Article Title: CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms

Journal Title: European Journal of Cancer

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ejca.2024.114192

Content Type: article

Copyright: © 2024 The Authors. Published by Elsevier Ltd.